Ep. 390 - Live from Amsterdam: Grand Rounds Europe takeaways

Cross-disease mechanisms (mitochondria, aging, prevention) and genetic-target skepticism, spurred by Novartis's LPA failure, dominated Grand Rounds Europe discussion.

• Cross-disease mechanisms sought: Post-GLP-1, panelists highlighted mitochondrial health (Luke O'Neill's "enemy within" framework) and women's/sleep biology as potential broad health-span levers.
• Prevention over treatment: Panelists across immunology, cardiovascular and infectious disease emphasized intervening earlier at fundamental mechanisms rather than treating late-stage, named-indication disease.

Themes, sentiment and reasons are AI-written paraphrases, checked so they never quote an episode. They may contain errors. Not investment advice. Episodes remain the property of their creators.